ArticleBJC reports2024
The natural history of neurolymphomatosis.
Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Facial diplegia as the first manifestation of Burkitt lymphoma with a Guillain-Barré syndrome-like presentation: a case report.BMC neurology · 2026Article
- Julio Óscar Trelles Montes (1904-1990).Journal of neurology · 2026Article
- Article
- Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.Internal medicine (Tokyo, Japan) · 2026Article
- Neurolymphomatosis: A Comprehensive Review of Clinical and Imaging Features.Radiology. Imaging cancer · 2026Review
- Case Report: Neurolymphomatosis of the sciatic nerve as a presentation of relapsed diffuse large B-cell lymphoma.Frontiers in oncology · 2026Article
- Clinical Spectrum, Diagnostic Work-up, and Outcomes of Neurolymphomatosis in Lymphoid Malignancies: A 10-Patient Case Series.Blood and lymphatic cancer : targets and therapy · 2026Article
- Efficacy of PR2-based immunotherapy in the treatment of diffuse large B-cell lymphoma-associated neurolymphomatosis: A report on two cases.Annals of hematology · 2025Article
- Primary Neurolymphomatosis: A Literature Review.European journal of neurology · 2025Review
- Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis.Annals of hematology · 2025Article
- Surgical treatment of rare peripheral nerve lesions: long-term outcomes and quality of life.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurolymphomatosis is a lymphoid malignancy of the peripheral nervous system and its natural history is poorly understood.
methodsWe performed PubMed search and extracted clinical data for Kaplan-Meier statistics to determine outcome parameters over time. Kruskal-Wallis test was performed to compare prognostic factors.
resultsOur search identified 559 patients and their median age was 61 years. Median overall survival (OS) was 12.0 (range 10.0-15.0) months. Diffuse large B-cell lymphoma was the most frequent histology, involving the brachial plexus, cranial nerves, and sciatic nerve. None had molecular profiling. There was a progressive lengthening of OS in successive decades, from 0.5 (95% CI 0.0-0.8) to 26.4 (95% CI 18.0-34.8) months between 1951 and 2022 (r DISCUSSION: Better outcome for patients with neurolymphomatosis is noted over time. But timely diagnosis remains a major problem that needs improvement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.